Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

344 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Effect of dialysis dose and membrane flux in maintenance hemodialysis.
Eknoyan G, Beck GJ, Cheung AK, Daugirdas JT, Greene T, Kusek JW, Allon M, Bailey J, Delmez JA, Depner TA, Dwyer JT, Levey AS, Levin NW, Milford E, Ornt DB, Rocco MV, Schulman G, Schwab SJ, Teehan BP, Toto R; Hemodialysis (HEMO) Study Group. Eknoyan G, et al. Among authors: toto r. N Engl J Med. 2002 Dec 19;347(25):2010-9. doi: 10.1056/NEJMoa021583. N Engl J Med. 2002. PMID: 12490682 Free article. Clinical Trial.
Proteinuria and other markers of chronic kidney disease: a position statement of the national kidney foundation (NKF) and the national institute of diabetes and digestive and kidney diseases (NIDDK).
Eknoyan G, Hostetter T, Bakris GL, Hebert L, Levey AS, Parving HH, Steffes MW, Toto R. Eknoyan G, et al. Among authors: toto r. Am J Kidney Dis. 2003 Oct;42(4):617-22. doi: 10.1016/s0272-6386(03)00826-6. Am J Kidney Dis. 2003. PMID: 14520612 Review. No abstract available.
Dialysis dose and the effect of gender and body size on outcome in the HEMO Study.
Depner T, Daugirdas J, Greene T, Allon M, Beck G, Chumlea C, Delmez J, Gotch F, Kusek J, Levin N, Macon E, Milford E, Owen W, Star R, Toto R, Eknoyan G; Hemodialysis Study Group. Depner T, et al. Among authors: toto r. Kidney Int. 2004 Apr;65(4):1386-94. doi: 10.1111/j.1523-1755.2004.00519.x. Kidney Int. 2004. PMID: 15086479 Free article. Clinical Trial.
Cardiac diseases in maintenance hemodialysis patients: results of the HEMO Study.
Cheung AK, Sarnak MJ, Yan G, Berkoben M, Heyka R, Kaufman A, Lewis J, Rocco M, Toto R, Windus D, Ornt D, Levey AS; HEMO Study Group. Cheung AK, et al. Among authors: toto r. Kidney Int. 2004 Jun;65(6):2380-9. doi: 10.1111/j.1523-1755.2004.00657.x. Kidney Int. 2004. PMID: 15149351 Free article. Clinical Trial.
A comparison of iothalamate-GFR and serum creatinine-based outcomes: acceleration in the rate of GFR decline in the African American Study of Kidney Disease and Hypertension.
Lewis J, Greene T, Appel L, Contreras G, Douglas J, Lash J, Toto R, Van Lente F, Wang X, Wright JT Jr; AASK Study Group. Lewis J, et al. Among authors: toto r. J Am Soc Nephrol. 2004 Dec;15(12):3175-83. doi: 10.1097/01.ASN.0000146688.74084.A3. J Am Soc Nephrol. 2004. PMID: 15579521 Clinical Trial.
Association of achieved dialysis dose with mortality in the hemodialysis study: an example of "dose-targeting bias".
Greene T, Daugirdas J, Depner T, Allon M, Beck G, Chumlea C, Delmez J, Gotch F, Kusek JW, Levin N, Owen W, Schulman G, Star R, Toto R, Eknoyan G; Hemodialysis Study Group. Greene T, et al. Among authors: toto r. J Am Soc Nephrol. 2005 Nov;16(11):3371-80. doi: 10.1681/ASN.2005030321. Epub 2005 Sep 28. J Am Soc Nephrol. 2005. PMID: 16192421 Clinical Trial.
A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease.
Pfeffer MA, Burdmann EA, Chen CY, Cooper ME, de Zeeuw D, Eckardt KU, Feyzi JM, Ivanovich P, Kewalramani R, Levey AS, Lewis EF, McGill JB, McMurray JJ, Parfrey P, Parving HH, Remuzzi G, Singh AK, Solomon SD, Toto R; TREAT Investigators. Pfeffer MA, et al. Among authors: toto r. N Engl J Med. 2009 Nov 19;361(21):2019-32. doi: 10.1056/NEJMoa0907845. Epub 2009 Oct 30. N Engl J Med. 2009. PMID: 19880844 Free article. Clinical Trial.
Erythropoietic response and outcomes in kidney disease and type 2 diabetes.
Solomon SD, Uno H, Lewis EF, Eckardt KU, Lin J, Burdmann EA, de Zeeuw D, Ivanovich P, Levey AS, Parfrey P, Remuzzi G, Singh AK, Toto R, Huang F, Rossert J, McMurray JJ, Pfeffer MA; Trial to Reduce Cardiovascular Events with Aranesp Therapy (TREAT) Investigators. Solomon SD, et al. Among authors: toto r. N Engl J Med. 2010 Sep 16;363(12):1146-55. doi: 10.1056/NEJMoa1005109. N Engl J Med. 2010. PMID: 20843249 Free article. Clinical Trial.
344 results